Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

NCT04641728 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Olaparib

Sponsor

Saitama Medical University International Medical Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]